Cardiff Oncology
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 31
- Market Cap
- -
- Introduction
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Th...
Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 90
- Registration Number
- NCT06106308
- Locations
- ๐บ๐ธ
The University of Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
๐บ๐ธMayo Clinic - Arizona, Phoenix, Arizona, United States
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 23
- Registration Number
- NCT05593328
- Locations
- ๐บ๐ธ
San Juan Oncology Associates, Farmington, New Mexico, United States
๐บ๐ธPacific Cancer Medical Center, Anaheim, California, United States
๐บ๐ธWashington University School of Medicine Center for Advanced Medicine, Saint Louis, Missouri, United States
Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 43
- Registration Number
- NCT04752696
- Locations
- ๐บ๐ธ
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
๐บ๐ธInova Schar Cancer Institute, Fairfax, Virginia, United States
๐บ๐ธMayo Clinic Rochester, Rochester, Minnesota, United States
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Cardiff Oncology
- Registration Number
- NCT04446793
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 68
- Registration Number
- NCT03829410
- Locations
- ๐บ๐ธ
Inova Schar Cancer Institute, Fairfax, Virginia, United States
๐บ๐ธCARTI Cancer Center, Little Rock, Arkansas, United States
๐บ๐ธMayo Clinic Florida, Jacksonville, Florida, United States
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03414034
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03303339
- Locations
- ๐บ๐ธ
Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States
๐บ๐ธUniversity of Kansas Cancer Center, Westwood, Kansas, United States
๐บ๐ธUniversity of California Los Angeles, Los Angeles, California, United States